NXC-201

Cell therapy

Also known as HBI0101

Earlyevidence

Evidence outlook

Early-stage evidence only

Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.

Also in development:AL Amyloidosis

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 1 (1)
Other / comorbidity
NCT07085676 · Polina Stepensky
2024-09-01 – 2030-11-01 · Systemic Sclerosis (SSc), Idiopathic Inflammatory Myopathy (IIM), Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Multiple Sclerosis (MS) Primary Progressive, Multiple Sclerosis (MS) Secondary Progressive, Neuromyelitis Optica Spectrum Disorder (NMOSD), Myasthenia Gravis (MG), Antiphospholipid Antibody Syndrome
What this study did

Competitive landscape

This drug's own stage for AL Amyloidosis: Stage not on record. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
NXC-201: this drugStage not on recordCell therapyBCMA (TNFRSF17)Weak signal
NCT06097832: NEXICART-2 interim (n=45, Sept 2026 8-K): 89% (40/45) IRC-assessed complete response (CR) rate, with 4 additional patients MRD-negative (up to 98% potential CR); 0 relapses observed to date; no ICANS or enterocolitis reported.
Anselamimab (Amlypave)Phase 3Monoclonal antibody—not yet gradedNo reviewed efficacy summary in this indication
DaratumumabPhase 3Monoclonal antibodyCD38not yet gradedNo reviewed efficacy summary in this indication
EtentamigPhase 3Multispecific antibodyBCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
SCTC21CPhase 3Biologic (subtype unspecified)CD38not yet gradedNo reviewed efficacy summary in this indication
BirtamimabDiscontinuedMonoclonal antibodyMisfolded immunoglobulin light chain (AL amyloid)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Coming up

14 December 2026PresentationNEXICART-2 45-patient interim results oral presentation at ASH 2026
US · Immix Biopharma, Inc. · Source ↗

Recent

29 September 2026Topline resultNEXICART-2 interim update: 89% (40/45) IRC-assessed CR rate
US · Immix Biopharma, Inc. · Source ↗